Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Universita' Degli Studi Di Verona has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. POLIAKOVA-GEORGAN, EKATERINA is the busiest examiner, with 1 busiest examiner pending action.
The 1 pending office action is being reviewed by 1 distinct examiner. POLIAKOVA-GEORGAN, EKATERINA is responsible for 1 busiest examiner pending action. This case is situated within 1 distinct art unit, showing a focused examination process for the university's Biotechnology & Pharmaceuticals portfolio. With only 1 pending office action, the administrative burden is minimal. POLIAKOVA-GEORGAN, EKATERINA handles 1 busiest examiner pending action, meaning the university's current success depends on this single examiner's review. The 1 distinct art unit involved indicates that the technology falls into a specific niche. For this 1 pending office action, the applicant will work exclusively with POLIAKOVA-GEORGAN, EKATERINA to address any outstanding issues raised by the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715327 | NANOPARTICLES FOR RELEASE OF NUCLEIC ACIDS | BAEK, BONG-SOOK | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18715327 | NANOPARTICLES FOR RELEASE OF NUCLEIC ACIDS | BAEK, BONG-SOOK | 1611 | §103 | Final Rejection | — | Pending | Jun 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversita Degli Studi Di Verona has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bong-Sook Baek has the most, with 1 of Universita Degli Studi Di Verona's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
